167 related articles for article (PubMed ID: 21739328)
21. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
[TBL] [Abstract][Full Text] [Related]
22. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
23. Development and psychometric evaluation of the urgency questionnaire for evaluating severity and health-related quality of life impact of urinary urgency in overactive bladder.
Coyne KS; Sexton CC; Thompson C; Bavendam T; Brubaker L
Int Urogynecol J; 2015 Mar; 26(3):373-82. PubMed ID: 24942375
[TBL] [Abstract][Full Text] [Related]
24. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder.
Coyne KS; Matza LS; Kopp Z; Abrams P
Eur Urol; 2006 Jun; 49(6):1079-86. PubMed ID: 16460875
[TBL] [Abstract][Full Text] [Related]
25. Psychometric equivalence of the OAB-q in Danish, German, Polish, Swedish, and Turkish.
Coyne KS; Margolis MK; Thompson C; Kopp Z
Value Health; 2008 Dec; 11(7):1096-101. PubMed ID: 18489500
[TBL] [Abstract][Full Text] [Related]
26. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study.
Wyndaele JJ; Goldfischer ER; Morrow JD; Gong J; Tseng LJ; Guan Z; Choo MS
Int J Clin Pract; 2009 Apr; 63(4):560-7. PubMed ID: 19348029
[TBL] [Abstract][Full Text] [Related]
27. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
28. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial.
Wagg A; Khullar V; Marschall-Kehrel D; Michel MC; Oelke M; Darekar A; Bitoun CE; Weinstein D; Osterloh I
J Am Geriatr Soc; 2013 Feb; 61(2):185-93. PubMed ID: 23350833
[TBL] [Abstract][Full Text] [Related]
29. The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women.
Chughtai B; Forde JC; Buck J; Asfaw T; Lee R; Te AE; Kaplan SA
Post Reprod Health; 2016 Mar; 22(1):34-40. PubMed ID: 26883688
[TBL] [Abstract][Full Text] [Related]
30. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
31. The validation of the Dutch OAB-q SF: An overactive bladder symptom bother and health-related quality of life short-form questionnaire.
Groenendijk IM; Scheepe JR; Noordhoff TC; Blok BFM
Neurourol Urodyn; 2019 Aug; 38(6):1775-1782. PubMed ID: 31215693
[TBL] [Abstract][Full Text] [Related]
32. The psychometric validation of the OAB family impact measure (OAB-FIM).
Coyne KS; Matza LS; Brewster-Jordan J; Thompson C; Bavendam T
Neurourol Urodyn; 2010 Mar; 29(3):359-69. PubMed ID: 19274760
[TBL] [Abstract][Full Text] [Related]
33. Should we use the shorter Thai-version quality of life and symptoms questionnaires in women with overactive bladder?
Bunyavejchevin S; Liao L; Lu SH; Choo MS; Rabbani KJ; Havanond P
J Obstet Gynaecol Res; 2015 Aug; 41(8):1260-5. PubMed ID: 26081949
[TBL] [Abstract][Full Text] [Related]
34. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
[TBL] [Abstract][Full Text] [Related]
35. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q.
Coyne K; Revicki D; Hunt T; Corey R; Stewart W; Bentkover J; Kurth H; Abrams P
Qual Life Res; 2002 Sep; 11(6):563-74. PubMed ID: 12206577
[TBL] [Abstract][Full Text] [Related]
36. Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents?
Herschorn S; Kaplan SA; Sun F; Ntanios F
Urology; 2014 May; 83(5):1023-9. PubMed ID: 24582119
[TBL] [Abstract][Full Text] [Related]
37. Validation of the Overactive Bladder-Bladder Assessment Tool (OAB-BAT): A Potential Alternative to the Standard Bladder Diary for Monitoring OAB Outcomes.
Chapple C; Kelleher C; Siddiqui E; Andrae DA; Johnson N; Payne C; Homma Y; Hakimi Z; Evans C; Lyn N; Kopp Z
Eur Urol Focus; 2021 Sep; 7(5):1176-1183. PubMed ID: 33451958
[TBL] [Abstract][Full Text] [Related]
38. Reproducibility study of Overactive Bladder Symptom Score questionnaire and its response to treatment (RESORT) in Korean population with overactive bladder symptoms.
Jeong SJ; Homma Y; Oh SJ
Qual Life Res; 2014 Feb; 23(1):285-92. PubMed ID: 23715806
[TBL] [Abstract][Full Text] [Related]
39. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
Nitti VW; Rovner ES; Bavendam T
BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062
[TBL] [Abstract][Full Text] [Related]
40. Validation of the 4 week recall version of the Uterine Fibroid Symptom and Health-related Quality of Life (UFS-QOL) Questionnaire.
Coyne KS; Soliman AM; Margolis MK; Thompson CL; Chwalisz K
Curr Med Res Opin; 2017 Feb; 33(2):193-200. PubMed ID: 27733082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
